This page will host Events plug-in for all Clarion and trade events.

Upcoming Events

View Calendar
Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

31.53 +0.27 (+0.86%)
Streaming Delayed Price Updated: 2:34 PM EDT, Jul 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Top S&P500 movers in Thursday's session
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
Moderna Stock Looks Ripe for a Short Squeeze
Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze 
Via MarketBeat
Topics Government
Moderna Reverses Its Rally As It Faces Another Vaccine Setback
The company previously guided to a longer timeline for its Covid/flu shot. But Wednesday's news introduces some data risk. 
Via Investor's Business Daily
Moderna Pulls Application For Seasonal Flu, Covid Combination Vaccine: But Retail Gets More Bullish
Moderna will resubmit the application later this year after data from its ongoing late-stage trial of its seasonal flu vaccine is available. 
Via Stocktwits
How Is The Market Feeling About Moderna?
Via Benzinga
Hedge Funds Are Building A Towering Wall Of Bets Against Stocks
After a sharp 23% rebound in the S&P 500 since April, hedge funds are now stacking record levels of bearish bets against stocks as investors question the staying power of the tariff-relief rally. 
Via Benzinga
Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr.
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter... 
Via Benzinga
What's Going On With Vaccine Stocks Today?
Shares of Vaccine stocks are moving higher on Tuesday after documents from the U.S. Food and Drug Administration revealed that its advisers will meet this week. 
Via Benzinga
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Stay informed about the most active stocks in the S&P500 index on Tuesday's session.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
Moderna (MRNA) Stock Trades Up, Here Is Why
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7% in the afternoon session after the FDA announced new regulatory guidelines that still allow quick COVID vaccine approvals for seniors and... 
Via StockStory
Topics Government World Trade
FDA Sets New Guidelines For Approving COVID-19 Booster Shots In Healthy Individuals: Moderna, Novavax Stocks Rise
The agency plans to demand stronger evidence of efficacy for the shots before approval is granted for healthy persons, between the ages of six months and 64 years, with no risk factors for severe... 
Via Stocktwits
Exploring the top movers within the S&P500 index during today's session.
Stay updated with the movements of the S&P500 index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.
The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness. 
Via Investor's Business Daily
Topics Bankruptcy Government
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
Stocks Mixed, Treasury Bonds Slip On Moody's US Downgrade: What's Driving Markets Monday?
U.S. stocks trimmed early-session losses by midday Monday, as investors showed limited concern after Moody's downgraded U.S. sovereign credit from Aaa to Aa1, effectively stripping the world's largest... 
Via Benzinga
Topics Economy
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
Discover which S&P500 stocks are making waves on Friday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid
Via The Motley Fool
MRNA Q1 Earnings Call: Management Focuses on Cost Reductions and Pipeline Progress Amid Revenue Shortfall
Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2... 
Via StockStory
Stay informed with the top movers within the S&P500 index on Wednesday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session. 
Via Chartmill
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
Via ACCESS Newswire
Top gainers and losers in the S&P500 index during Wednesday's after-hours session.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers. 
Via Chartmill
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN)
Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.